Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
Year: 2012
Type: article
Source: Blood
Authors: Dong-Wook Kim, Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil Shah, Hagop M. Kantarjian, The PACE Study Group
Institutions: The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Charité - Universitätsmedizin Berlin, University of California, Los Angeles, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hôpital Lyon Sud, Hammersmith Hospital, Imperial College London, Emory University, Winship Cancer Institute, University of Michigan, Washington University in St. Louis, Dana-Farber Cancer Institute, University of Rome Tor Vergata, St. Eugenio Hospital, Hôpital Saint-Louis, Recherche clinique appliquée à l'hématologie, University of Bologna, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, ARIAD Pharmaceuticals (United States), Centre Hospitalier Universitaire de Poitiers, University of Utah, Huntsman Cancer Institute, Jena University Hospital, South Australia Pathology, Royal Adelaide Hospital, University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2561790498